Numerous influenza pandemics in the last century resulted in the death of millions of people worldwide. With the current and future threats of influenza pandemics development of new antiviral compounds remains a great demand. However, currently only a limited number of drugs are available for the treatment and prophylaxis of influenza. A neuraminidase (NA) inhibitor, oseltamivir phosphate, is the most commonly used antiviral drug. However, a number of reports suggest the emergence of oseltamivir phosphate resistance in new seasonal influenza viruses and highly pathogenic avian influenza (H5N1) (for example, [@B1]).

(--)-Epigallocatechin-3-*O*-gallate (EGCG: **1**), a major component of green tea plant (*Camellia sinensis*), has been recognized to possess antiviral properties. Reports on the anti-influenza activity of **1** found that it inhibited virus adsorption ([@B5]), as well as acidification of endosomes and lysosomes ([@B2]). Such virus inhibition activity is different from other current NA or proton pump inhibitors, suggesting that **1** can be developed into a new class of antiviral compounds that are effective against current drug resistant influenza strains. However, **1** has not been used as an antiviral compound because of its poor lipid membrane permeability and low chemical stability. It was previously reported that the introduction of long alkyl chain groups to **1** improved its lipid membrane permeability ([@B6]), while protection of its hydroxyl groups with acyl groups increased its chemical stability under physiological conditions ([@B3]). Recently, we reported a method to synthesize EGCG-fatty acid monoesters using lipase-catalyzed transesterification and demonstrated that EGCG-fatty acids monoesters possessed improved influenza virus inhibitory effect against influenza A/PR8/34/(H1N1) in an alkyl length dependent manner ([@B4]). Here, we investigated the spectrum of influenza virus inhibition activity of EGCG (**1**) and EGCG-C-16 (**2**). As shown in [Figures 1a](#F1){ref-type="fig"}, **2** is a mixture of four regio-isomers and the ratio of each regio-isomer 2a:2b:2c:2d is 38:35:7:20, respectively. Because the B-ring-modified esters (2a and 2b) and D-ring-modified esters (2c and 2d) showed exactly the same antiviral activities (data not shown), we used the mixture of four regio-isomers (2a-d) in the following assays.

![**A.** Chemical structure of EGCG (**1**) and EGCG-C16 (**2**). **2** is a mixture of four regio-isomers (**2a-d**). **2a**: R^2^=R^3^= R^4^=H, R^1^= CO(CH)~14~CH~3~, **2b**: R^1^=R^3^=R^4^=H, R^2^= CO(CH)~14~CH~3~, **2c**: R^1^=R^2^=R^4^=H, R^3^= CO(CH)~14~CH~3~, **2d**: R^1^=R^2^=R^3^=H, R^4^= CO(CH)~14~CH~3.~ **B**. Avian influenza virus inhibition activity of 1 and 2 in chicken embryonated eggs. Influenza A/Duck/Hong Kong/342/78 (H5N2) was pretreated with or without 1.0μM compounds and then inoculated (50 pfu/egg) into the allantoic fluid of embryonated eggs for 7 days at 37°C. Open circle, no compound; Closed circle, 1.0μM EGCG-16 (**2**); Open square, 1.0μM EGCG (**1**); Closed square, 1.0μM Zanamivir; Open lozenge, 1.0μM Oseltamivir phosphate.](jmgm-03-195-g001){#F1}

A series of human influenza viruses, an experimental strain (A/Puerto Rico/8/34/(H1N1)), vaccine strains (A/Beijing/262/95/(H1N1), A/Panama/2007/99/(H3N2), and B/Yamanashi/166/98/), drug-resistant strains (Yokohama/77/2008/(H1N1) OPR: oseltamivir phosphate-resistant (OPR), Yokohama/63/2007/(H1N1) AR: amantadine-resistant (AR), A/Yokohama/91/2008/(H1N1) OPR/AR: (OPR/AR) and avian pathogenic influenza (A/Duck/Hong Kong/342/78/(H5N2)), were directly incubated with **1** or **2** for 30 min prior to inoculation into MDCK cells. The cells were inoculated with virus, with or without the compounds, for 1hr, and the direct virus inhibitory effects were assessed by a plaque formation assay at 54hr post-incubation. The plaque inhibition activity was calculated relative to no compound. The cytotoxicity of compounds on MDCK cells were evaluated by the MTT cell proliferation assay. Briefly, the cells were incubated with **1** or **2** for 24hr for the MTT assay. The results of the plaque inhibition assay and MTT assay are expressed as mean ± standard error of three independent experiments.

We also investigated the virus inhibition activity of **1** and **2** on avian influenza A/Duck/Hong Kong/342/78 (H5N2) virus *in ovo* using 11-day-old chicken embryonated eggs (n=12) inoculated with compound-treated or untreated viruses.

As shown in [Table 1](#T1){ref-type="table"}, both **1** and **2** showed broad virus inhibitory effects on MDCK cells. The EC~50~ values of **2** on these viruses were between 10 to 61nM, which were approximately 7.1 to 44-fold lower than those of **1**. The CC~50~ value of **2** was 82μM, which was only 3.1-fold lower than that of **1** (255 μM). Thus, the SI value of **2** was improved 2.2 to 14-fold compared to **1**.

###### 

Direct virus inhibitory effect of **1** and **2** based on the plaque formation assay

                                                          Direct virus inhibitory effect[^a^](#a){ref-type="fn"}   SI[^b^](#b){ref-type="fn"}          
  ------------------------------------------------------- -------------------------------------------------------- ---------------------------- ------ ------
  A/Puerto Rico8/34 (H1N1)                                0.391±0.056                                              0.020±0.007                  653    4062
  A/Beijing/262/95 (H1N1)                                 0.436±0.081                                              0.061±0.008                  585    1331
  A/Yokohama/77/2008 (H1N1) OPR[^e^](#e){ref-type="fn"}   0.400±0.042                                              0.017±0.008                  638    4779
  A/Yokohama/63/2008 (H1N1) AR[^f^](#f){ref-type="fn"}    0.540±0.042                                              0.027±0.008                  472    3009
  A/Yokohama/91/2008 (H1N1) OPR/AR                        0.597±0.015                                              0.036±0.012                  427    2256
  A/Panama/2007/99 (H3N2)                                 0.173±0.006                                              0.010±0.004                  1476   8125
  A/Duck/Hong Kong/342/78 (H5N2)                          0.657±0.022                                              0.015±0.006                  388    5416
  B/Yamanashi/166/98                                      0.490±0.053                                              0.024±0.008                  521    3385

Direct virus inhibitory effect: Virus treated with **1** or **2** for 30min at 37 ºC prior to the inoculation and then inoculated for 2 days at 37ºC. MDCK cells, MIO: 2.5 x 10^−4^ pfu/cell.

SI (selectivity index) is the ratio of CC~50~ and EG~50~.

EC~50~ represents the concentration of compound required to reduce plaque number by 50% relative to the control well without test compound.

CC~50~ represents the concentration of compound required to reduce cell viability by 50% relative to the control well without test compound. The CC~50~ for **1** and **2** were 255.7 ± 6.0 and 81.2 ± 12.5μM, respectively.

OPR: oseltamivir phosphate-resistant virus

AR: amantadine-resistant virus

With respect to the avian influenza virus inhibition assay *in ovo*, virus treated with **1**, zanamivir, or oseltamivir phosphate showed a moderate viral inhibitory effect ([Figures 1b](#F1){ref-type="fig"}). However, **2** almost completely inhibited the infection ([Figures. 1b](#F1){ref-type="fig"}), and the efficacy was retained even at 0.1μM (data not shown).

In summary, **2** inhibited human and avian influenza A and B viruses, including drug-resistant viruses. **2** was found to be more effective than neuraminidase inhibitors, and strongly inhibited the infection of avian influenza (H5N2) virus in chicken embryonated eggs. This unique viral inhibitory action has the potential to be utilized to effectively control a broad spectrum of influenza viruses.
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